Unlikely to cause harm — often a labeling or packaging issue.
Subpotent Drug: Out-of-Specification test results observed in assay test at 21-month long term stability study.
| Brand name | AMLODIPINE BESYLATE |
| Generic name | AMLODIPINE BESYLATE |
| Active ingredient(s) | AMLODIPINE BESYLATE |
| Distributed by / for | Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 U.S |
| NDC | 68180-721-03 |
| Full product label | Amlodipine Besylate Tablets, USP 10 mg, 1000-count bottles, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 U.S, Manufactured by: Lupin Limited, Aurangabad 431 210 India, NDC 68180-721-03 |
| Recalling firm | Lupin Pharmaceuticals Inc. |
| Distribution | Product was distributed directly to three distributors in TN and NJ. Product may have been further distributed throughout the United States. |
| Quantity | 3,096 bottles |
| Recall initiated | 2023-06-27 |
| Report date | 2023-07-19 |
| Recall completed | 2024-03-12 |
| Recall number | D-0899-2023 |
| Classification | Class III |
| FDA status | Terminated |
| Origin on file | Baltimore MD United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗